Amivantamab (Rybrevant)

Bispecific monoclonal antibody (EGFR/MET-directed antineoplastic)

Amivantamab (Rybrevant)

Forms and strengths
Form: TabletStrength: 350 mg/7 mL (50 mg/mL) single-use vial
Print

Indication

  • Amivantamab, combined with lazertinib, is used as first-line treatment for advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations.
  • Amivantamab, combined with carboplatin and pemetrexed chemotherapy, is used for NSCLC with EGFR exon 19 deletion or exon 21 L858R mutations that has progressed after osimertinib treatment.
  • Amivantamab, combined with carboplatin and pemetrexed, is used as first-line treatment for NSCLC with EGFR exon 20 insertion mutations.
  • Amivantamab, used alone, is used for NSCLC with EGFR exon 20 insertion mutations that has progressed after platinum-based chemotherapy.
  • Tumor tissue must be tested and confirmed to carry the relevant EGFR mutation before starting treatment.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.